The global oncology market size was USD 201.80 billion in 2023, calculated at USD 225.01 billion in 2024 and is expected to reach around USD 668.26 billion by 2034, expanding at a CAGR of 11.5% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oncology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oncology Market, by Indication Type, 2024-2034
8.1.1. Lungs Cancer
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Colorectal Cancer
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Breast Cancer
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Liver Cancer
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Bladder Cancer
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Head & Neck Cancer
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Prostate Cancer
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2021-2034)
9.1. Oncology Market, by Cancer Diagnostics & Treatment, 2024-2034
9.1.1. Cancer Diagnostics (Biopsy, Imaging, Immunohistochemistry, Tumor Biomarkers Test, In Situ Hybridization, Liquid Biopsy)
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Cancer Treatment (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others)
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Indication (2021-2034)
10.1.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2034)
11.1. Aegerion Pharmaceuticals Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Abbvie Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Ability Pharma
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Acadia Pharmaceuticals Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Amgen Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Takeda Oncology
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Aslan Pharmaceuticals Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Aspen Pharmacare Holdings Limited.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Astrazeneca
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Athenex, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample